Brexogen’s Exosome Therapy for Atopic Dermatitis, ‘BRE-AD01’ Accepted for Phase 1 Clinical Trials by US FDA – QNT Press Release

First entry to clinical trial of exosome for atopic dermatitis

The first exosome-based therapeutics in US clinical trial among Korean companies

SEOUL, South Korea, Nov. 2, 2022 /PRNewswire/ — The US FDA granted the initiation of the phase 1 clinical trial of ‘BRE-AD01’, an exosome-based therapy for atopic dermatitis. ‘BRE-AD01’ is being developed by Brexogen with its own exosome-platform technology . It is the first phase 1 clinical trial of therapeutic exosome for atopic dermatitis in major countries. This IND clearance is very meaningful in that patients with atopic dermatitis can benefit from receiving better treatment with ‘BRE-AD01’, which is armed with multiple mode of action.

Full story available on

Source link

Recommended For You

About the Author: News Center